• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

GeneDx Launches Tool to Fuel Rare Disease Drug Discovery

by Fred Pennic 11/20/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– GeneDx, a leader in genomic insights, has announced the launch of GeneDx Discover, a groundbreaking data visualization tool designed to revolutionize drug discovery and development. 

– The platform provides biopharmaceutical companies with access to de-identified and aggregated genetic data, empowering them to accelerate the development of new therapies.

Addressing the Challenges of Drug Development

The traditional drug development process is lengthy, costly, and often unsuccessful. On average, it takes 12 years and $2.6 billion to bring a new drug to market, with a 90% failure rate. GeneDx Discover aims to address these challenges by leveraging the power of genetic data to improve decision-making and accelerate the development timeline.

Unlocking the Potential of Genetic Data

GeneDx Discover provides biopharmaceutical companies with:

  • Access to a vast dataset: Leverages GeneDx’s industry-leading database of over 700,000 clinical exomes and genomes.
  • Self-service data exploration: Offers an easy-to-use interface for exploring and analyzing genetic data.
  • Deeper understanding of patient populations: Provides insights into disease prevalence, phenotypic information, and variant-level details.
  • Enhanced decision-making: Enables data-driven decisions throughout the drug development process.
  • Accelerated development timelines: Helps identify promising drug candidates and streamline clinical trials.

GeneDx Discover is the latest addition to GeneDx’s portfolio of solutions aimed at improving health outcomes through genomic insights. The company is committed to collaborating with biopharmaceutical companies to accelerate drug development, expand access to genetic testing, and ultimately improve patient care.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Drug Discovery

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

Why Brain Health Is Entering Its Infrastructure Era

Brain Health’s Infrastructure Era: Proving Clinical Outcomes with Integrated Neuromotor Tracking

Why Catholic Health Inked a $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

Catholic Health Inks $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

The Real Risk in Healthcare AI Isn’t the Model. It’s the Data. 

Clinical Data Fidelity: The Real Blindspot in Healthcare AI Strategy

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

M&A: Qualtrics Completes $6.75B Acquisition of Press Ganey Forsta

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |